Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 57

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 57
---
3 research and development expenses amounted to $47,528 constituting the second largest expense recognized during that quarter.

Other Income

For the three months ended December 31 2024, the Company reported a net other expense of $(454,007), a substantial increase from the net other expense of $(22,151), in 2023. The increase was primarily driven by the recognition of a Derivative Loss of $(416,016) in 2024. For the quarter ended December 31, 2024 the Company also recognized higher interest and amortization expenses as compared to the quarter ended 2023.

<div align='center'>41</div>

Net Loss

The Company recognized an Operating Loss of $ 61,378 during the three months ended December 31 , 2024 whereas the Company recognized an Operating Loss of $ 122,782 for the same period ended 2023. The reduction in operating loss is primarily attributable to a reduction in Consulting and Professional Fees and Research and Development expenses incurred during the period ended 2024 as compared to the quarter ended in 2023.

Net Loss is $ 515,384 for the three months ended December 31, 2024 as opposed to a Net Loss of $144,933 for the same period ended 2023 the difference primarily attributable to the recognition by the Company of Derivative Loss of $ 416,016 during the three months ended December 31, 2024.

Working Capital

|                     |     |   | December 31 , 2024 |   |     |   | September 30, 2024 |   |
|:--------------------|:----|:--|-------------------:|:--|:----|:--|-------------------:|:--|
| Current assets      |     | $ |            173,683 |   |     | $ |            143,351 |   |
| Current liabilities |     |   |          5,870,459 |   |     |   |          5,378,456 |   |
| Working capital     |     | $ |         (5,696,776 | ) |     | $ |         (5,235,105 | ) |

Working capital deficit increased by $ 461,670 from September 30, 2024 to December 31, 2024, primarily due to increase in Derivative Liability.

Liquidity and Capital Resources

|                                                      |     | Quarter Ended |         |   |     |      |